SPATA19 and neoplasm: This revealed that the majority (>95%) of these expanded SPAS-1+ T cells in the IRE+ anti-CTLA-4 condition were in the tumor IV-neg gate and therefore concentrated in the tumor (Fig. 6d, e, g).